Tag: inactivated vaccines market trends

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Inactivated Vaccines Industry By 2029?

The market capacity of inactivated vaccines has been on a consistent growth trajectory in the past few years. Rising from $6.19 billion in 2024, it is expected to reach $6.37 billion in 2025. This signifies a compound annual growth rate (CAGR) of 2.8%. The growth observed in the historic period is resultant from efforts towards the eradication of polio, initiation of flu vaccination schemes, emergence of new infectious diseases and regulatory authorizations.

The market for inactivated vaccines is projected to experience consistent expansion in the coming years. It’s estimated to reach a value of “$7.58 billion by 2029,” progressing at a compound annual growth rate (CAGR) of 4.5%. This growth in the predicted timeframe can be linked to the preparedness for pandemics, increased vaccine coverage, advancements in biomanufacturing, and initiatives toward health equity. Key trends during this forecast period consist of mRNA vaccine platforms, combination vaccines, thermostable vaccines, and digital vaccine passports.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

What Underlying Factors Are Supporting The Inactivated Vaccines Market Growth?

The climbing rate of infectious diseases is projected to boost the expansion of the inactivated vaccine market. Pathogens like bacteria, viruses, fungi, or parasites cause infectious diseases that can be transmitted from one person to another, leading to diverse symptoms and health problems. An example of such a disease is Tuberculosis. Using inactivated or non-living pathogens, vaccines stimulate an immune response, efficiently thwarting diseases such as polio, hepatitis A, and influenza. A report by the Centers for the Disease Control and Prevention, a national public health agency in the US, noted in November 2023 that Tuberculosis cases in the US rose from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. This surge in infectious disease prevalence thus fuels the growth of the inactivated vaccine market.

What Is The Segment Breakdown Of The Inactivated Vaccines Market?

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:

1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

How Are Global Trends Impacting The Development Of The Inactivated Vaccines Market?

Leading firms in the inactivated vaccines market are developing and introducing new and improved inactivated vaccines to maintain their market dominance. Inactivated vaccines are made up of inactivated or killed virus particles, bacteria, or other pathogens which were grown in a culture. For example, in January 2022, GSK PLC, a pharmaceutical and biotechnology company headquartered in the UK, launched a new inactivated vaccine, Shingrix, aimed at helping to protect against shingles (Herpes zoster). Shingrix, a non-live, recombinant subunit adjuvanted vaccine, is given via two intramuscular injections. Initially, the vaccine was indicated for people aged 50 and above. However, its use has since been broadened to include those aged 18 and above who are at an increased risk of developing shingles due to immunodeficiency or immunosuppression arising from an identified disease or treatment.

Who Are The Leading Companies Driving The Inactivated Vaccines Market?

Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Which Region Is Leading Innovation In The Inactivated Vaccines Market?

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Inactivated Vaccines Market Through 2029?

The size of the inactivated vaccines market has been experiencing consistent growth over the past few years. The market, which was valued at $6.19 billion in 2024, is projected to increase to $6.37 billion in 2025, with a compound annual growth rate (CAGR) of 2.8%. This historical growth trend is linked to efforts to eradicate polio, the implementation of influenza immunisation programs, the emergence of new infectious diseases, and regulatory approvals.

The market size of inactivated vaccines is projected to experience consistent expansion in the upcoming years. It is set to reach “$7.58 billion by the year 2029, growing at a compound annual growth rate (CAGR) of 4.5%.” This growth during the forecast period can be associated with readiness for pandemics, wider vaccine coverage, advancements in biomanufacturing, and initiatives toward health equity. Key trends for this forecast period encompass mRNA vaccine platforms, combined vaccines, heat-stable vaccines, and digital vaccine passports.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

What Market Forces Are Driving The Inactivated Vaccines Sector In 2025 And Beyond?

The escalating occurrence of contagious diseases is forecasted to drive an expansion in the inactivated vaccine market. Contagious diseases, which are viruses, bacteria, parasites, or fungi-based illnesses that can be transmitted between individuals, produce a variety of symptoms and health issues. Tuberculosis is a prime example of such diseases. Inactivated vaccines, which use non-living pathogens to trigger an immune response, are highly effective in preventing diseases such as polio, hepatitis A, and influenza. In November 2023, the Centers for Disease Control and Prevention, a key national public health organization in the USA, published an article stating that the count of tuberculosis patients in the USA soared from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. As such, the escalating occurrence of contagious diseases is fueling expansion in the inactivated vaccine market.

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:

1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

Which Trends Are Redefining The Future Landscape Of The Inactivated Vaccines Industry?

Leading firms in the inactivated vaccines sector are introducing sophisticated and novel inactivated vaccines to maintain their market standing. An inactivated vaccine comprises inactivated pathogens including viruses, bacteria, or other microbes that have been cultured and subsequently killed to eliminate their disease-causing abilities. For example, in January 2022, GSK PLC, a pharmaceutical and biotechnology firm based in the UK, launched a fresh inactivated vaccine called Shingrix to help thwart shingles (Herpes zoster). Shingrix is a non-live, adjuvanted recombinant subunit vaccine given intramuscularly in two doses. Initially, the vaccine was indicated for people aged 50 and up, but its use has recently been extended to cover those aged 18 and up who have a higher risk of getting shingles due to immune deficiency or suppression resulting from a confirmed disease or therapy.

Which Firms Are Considered Leaders In The Inactivated Vaccines Market Space?

Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

What Role Do Regional Policies And Investments Play In Inactivated Vaccines Market Expansion?

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Inactivated Vaccines Market Size From 2025 to 2034?

The size of the inactivated vaccines market has been steadily expanding in recent times. It is anticipated to elevate from $6.19 billion in 2024 to $6.37 billion in 2025, with a compound annual growth rate (CAGR) of 2.8%. The previous growth can be credited to efforts to wipe out polio, influenza immunization schemes, the emergence of infectious diseases, and regulatory authorizations.

The market size of the inactivated vaccines is projected to experience consistent expansion in the coming years. By 2029, it is anticipated to reach $7.58 billion with a Compound Annual Growth Rate (CAGR) of 4.5%. Factors contributing to this anticipated augmentation in the outlook period include preparedness for pandemics, increased vaccine coverage, advancements in biomanufacturing, and health equity campaigns. The prediction period will also witness significant trends such as the use of mRNA vaccine platforms, combination vaccines, thermostable vaccines, and the introduction of digital vaccine passports.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theInactivated Vaccines Market?

The escalating occurrence of infectious diseases is predicted to drive the expansion of the inactivated vaccine market. Pathogens, including bacteria, viruses, fungi or parasites, cause infectious diseases which can transmit between people, leading to a variety of symptoms and health conditions, such as tuberculosis. Inactivated vaccines, which utilize non-living pathogens to trigger an immune response, are highly effective in preventing diseases like polio, hepatitis A and influenza. For example, in November 2023, the Centers for Disease Control and Prevention, a national public health organization based in the US, reported an increase in tuberculosis cases within the country from 8,320 in 2022 to 9,615 in 2023, which is an increase of 1,295 cases. Therefore, the escalating occurrence of infectious diseases is fueling the expansion of the inactivated vaccine market.

Which Segments in the Inactivated Vaccines Offer the Most Growth?

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:

1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theInactivated Vaccines Market?# Market?

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Current Market Growth and Trends in the Inactivated Vaccines Industry?

Leading corporations in the inactivated vaccines market are pioneering new and improved inactivated vaccines in an attempt to retain their market status. This type of vaccine includes deactivated virus particles, bacteria, or alternative pathogens, grown in a culture and then killed to eliminate their capacity to produce disease. To illustrate, in January 2022, GSK PLC, a pharmaceutical and biotechnology firm based in the UK, launched an innovative inactivated vaccine called Shingrix to help protect against shingles (Herpes zoster). Shingrix, a non-live, recombinant subunit adjuvanted vaccine, is given intramuscularly in two doses. Initially, the vaccine was recommended for individuals aged 50 and above, but its use has recently been extended to include those aged 18 and above who are at an increased risk of contracting shingles due to known illness-driven or treatment-driven immunodeficiency or immunosuppression.

View the full report here:

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

What Are the Key Elements That Define the Inactivated Vaccines Market?

Inactivated vaccines, also known as killed vaccines, are a type of vaccine that contains viruses or bacteria that have been killed or inactivated using heat, chemicals, or radiation. These vaccines are designed to stimulate an immune response without causing disease in the vaccinated individual.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13018

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Inactivated Vaccines Market Grown from 2024 to 2025?

The market size for inactivated vaccines has witnessed a consistent growth in the past few years. It is projected to expand from $6.19 billion in 2024 to $6.44 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.0%. The progressive growth during the historical period can be linked to initiatives aimed at eradicating polio, influenza immunization programs, the emergence of new infectious diseases, and regulatory approvals.

What Growth Rate Is Anticipated for the Inactivated Vaccines Market in the Coming Years?

The market for inactivated vaccines is projected to experience consistent expansion in the forthcoming years. The estimated growth will reach $7.75 billion in 2029, with a compound annual growth rate (CAGR) of 4.7%. The expected growth during this forecast period can be credited to pandemic readiness, increased vaccine coverage, advancements in biomanufacturing, and health equity initiatives. Some significant trends anticipated during the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, and digital vaccine passports.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

Who Are the Leading Companies in the Inactivated Vaccines Market?

Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

What Are the Key Drivers of the Inactivated Vaccines Market?

The rise in infectious diseases is predicted to spur the expansion of the inactivated vaccine industry. Infectious diseases, caused by pathogens such as bacteria, viruses, fungi, or parasites, can be transmitted from one individual to another and can generate an array of symptoms and health issues. Tuberculosis is an example of an infectious disease. Inactivated vaccines utilize non-living pathogens to prompt an immune response, effectively shielding from diseases such as polio, hepatitis A, and influenza. For instance, Centers for Disease Control and Prevention, a public health agency in the US, reported in November 2023 an increase in tuberculosis cases in the US from 8,320 in 2022 to 9,615 in 2023, showing a jump of 1,295 cases. Hence, the rising prevalence of infectious diseases is fueling the growth of the inactivated vaccine market. The escalation in immunization efforts is anticipated to drive forward the growth of the inactivated vaccines market. Immunization initiatives or programs are structured campaigns with the goal of vaccinating individuals or communities to shield them from certain infectious diseases. These growing efforts towards immunization significantly contribute to the inactivated vaccines sector. Intensified vaccination drives result in greater demand for inactivated vaccines, encouraging market expansion and prompting investments in research and development. For instance, according to the Switzerland-based intergovernmental organization, the World Health Organization, vaccines prevent the death of 4-5 million people worldwide each year by protecting against diseases such as hepatitis, diphtheria, tetanus, pertussis (whooping cough), measles, and polio. In 2022, about 84% of infants around the world received three doses of the polio vaccine. Simultaneously, it’s projected that 84% infants in nations using oral polio vaccine (OPV) received their first dose of inactivated polio vaccine (IPV) in the same year. Therefore, the escalating trend of immunization initiatives is fostering the growth of the inactivated vaccines market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

What Are the Key Market Segments in the Inactivated Vaccines Industry?

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:

1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

What Are the Latest Trends in the Inactivated Vaccines Market?

To remain competitive in the market for inactivated vaccines, key companies are launching advanced and innovative products. These types of vaccines consist of deactivated virus particles, bacteria, or any other pathogens—these microorganisms are cultured and subsequently killed to eliminate their ability to cause diseases. For instance, GSK PLC, a biotechnology and pharmaceutical enterprise stationed in the UK, launched a novel inactivated vaccine called Shingrix in January 2022. This is designed to offer protection against shingles (Herpes zoster). Shingrix, a non-live, recombinant subunit vaccine, is given via intramuscular injection in two separate doses. Initially, the vaccine was meant for those aged 50 years and up, but it has since been offered to those aged 18 years and above who are more susceptible to shingles due to immunodeficiency or immunosuppression related to specific illnesses or treatments.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

What Are the Key Regional Markets in the Inactivated Vaccines Industry?

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13018

This Report Delivers Insight On:

1. How big is the inactivated vaccines market, and how is it changing globally?

2. Who are the major companies in the inactivated vaccines market, and how are they performing?

3. What are the key opportunities and risks in the inactivated vaccines market right now?

4. Which products or customer segments are growing the most in the inactivated vaccines market?

5. What factors are helping or slowing down the growth of the inactivated vaccines market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theInactivated Vaccines Market?

The rising instances of infectious diseases are anticipated to fuel the inactivated vaccine market’s expansion in the future. Infectious diseases, which can be transmitted from one individual to another, are health issues prompted by pathogens like bacteria, fungi, viruses, or parasites. They cause a variety of symptoms and health issues, with tuberculosis being one such infectious ailment. Non-living pathogens are employed in inactivated vaccines to trigger an immune response, effectively safeguarding against diseases like polio, influenza, and hepatitis A. For example, there was a surge in the number of tuberculosis patients in the USA shown by data from the Centers for Disease Control and Prevention, a national public health agency in the US. The number rose from 8,320 in 2022 to 9,615 in 2023, a spike of 1,295 cases. Consequently, the escalation in infectious diseases is spurring the expansion of the inactivated vaccine market. An expected acceleration in immunization initiatives is set to propel the inactivated vaccines market’s growth further. Immunization initiatives are coordinated campaigns aimed at vaccinating individuals or communities against specific infectious diseases, which are key factors in inactivated vaccines. Amplified efforts in vaccination result in an increased demand for inactivated vaccines, thereby stimulating market growth and driving investments in research and development. For example, the World Health Organization, a Switzerland-based intergovernmental organization, reported in July 2023 that vaccines prohibit 4-5 million lives worldwide from being lost to infectious diseases such as hepatitis, diphtheria, tetanus, pertussis, measles, and polio every year. Furthermore, in 2022, approximately 84% of infants worldwide were administered three doses of the polio vaccine. In the same year, an estimated 84% of infants in countries utilizing the oral polio vaccine (OPV) were given their first dose of the inactivated polio vaccine (IPV). Thus, the growth in immunization initiatives is facilitating the expansion of the inactivated vaccines market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

#How Will the CAGR of the Inactivated Vaccines Market Influence Its Overall Growth by 2034?

The market size for inactivated vaccines has seen consistent growth in the past few years. This market is projected to increase from $6.19 billion in 2024 to $6.44 billion in 2025, representing a compound annual growth rate (CAGR) of 4.0%. Factors such as polio eradication initiatives, influenza immunization campaigns, newly emerging infectious diseases, and regulatory authorizations have contributed to the growth observed in the historic period.

The market size of inactivated vaccines is predicted to witness consistent expansion in the upcoming years, reaching an estimated value of $7.75 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 4.7%. This growth during the forecast period can be associated with factors like readiness for pandemics, greater vaccine coverage, progress in biomanufacturing, and initiatives for health equality. Important trends expected during this forecast period include mRNA vaccine platforms, combination vaccines, thermostable vaccines, and digital vaccine passports.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13018

What Are the Latest Innovations Influencing theInactivated Vaccines Market?

Leading enterprises in the inactivated vaccines market are developing and launching innovative inactivated vaccines to maintain their market dominance. An inactivated vaccine encompasses inactivated virus particles, bacteria, or any other pathogens cultivated in a lab and subsequently exterminated to eliminate their ability to cause diseases. For instance, in January 2022, GSK PLC, a biotechnology and pharmaceutical company based in the UK, introduced a novel inactivated vaccine called Shingrix to aid in the prevention of shingles (Herpes zoster). Shingrix is an adjuvanted, non-live, recombinant subunit vaccine administered via two intramuscular injections. Initially, the vaccine was intended for those aged 50 and above. However, its coverage has recently been extended to individuals who are 18 years and older, particularly vulnerable to shingles due to immune deficiencies or because of immunosuppression induced by a diagnosed disease or treatment.

Who Are the Major Industry Players Accelerating Growth in theInactivated Vaccines Market?

Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Which Primary Segments of the Inactivated Vaccines Market Are Driving Growth and Industry Transformations?

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:

1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theInactivated Vaccines Market?# Market?

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2025, By The Business Research Company:

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the Inactivated Vaccines market?

There has been consistent growth in the size of the inactivated vaccines market in the past few years. The market is projected to grow from $6.19 billion in 2024 to reach $6.44 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.0%. The growth witnessed during the historical period can be related to the efforts to eradicate polio, initiatives for influenza vaccination, the emergence of new infectious diseases, and regulatory approvals.

What will be the inactivated vaccines market size in the future?

The market for inactivated vaccines is predicted to witness consistent growth in the coming years. The market’s worth is projected to reach $7.75 billion by 2029, with a compound annual growth rate (CAGR) of 4.7%. This growth during the forecast period is linked to readiness for pandemics, increased vaccination coverage, improvements in biomanufacturing, and initiatives on health equity. Key trends during this predicted timeframe would be mRNA vaccine platforms, combination vaccines, thermostable vaccines, and digital vaccine passports.

Get your inactivated vaccines market report here!

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

What main drivers are fueling expansion in the inactivated vaccines market?

The rise in infectious diseases is projected to accelerate the expansion of the inactivated vaccine market. Infectious diseases, induced by bacteria, viruses, fungi, or parasites, can transfer from one person to another, resulting in a variety of symptoms and health issues. Tuberculosis is an example of an infectious disease. Non-living pathogens are used in inactivated vaccines to trigger an immune response, which effectively safeguards against illnesses like polio, hepatitis A, and influenza. For instance, an article from the Centers for Disease Control and Prevention, a US-based national public health agency, stated in November 2023 that there was a rise in tuberculosis patients in the USA from 8,320 in 2022 to 9,615 in 2023, amounting to an increase of 1,295 cases. Thus, the surge in infectious diseases is fueling the growth of the inactivated vaccine market.

Market Driver for Inactivated Vaccines: Growth of Inactivated Vaccines Market Propelled by Rising Immunization Initiatives

 

What key areas define the segmentation of the global inactivated vaccines market?

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:

1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

Who are the dominant players expanding their reach in the inactivated vaccines market?

Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

How are evolving market trends shaping inactivated vaccines Strategies?

Prominent businesses operating in the domain of inactivated vaccines are leveraging new and sophisticated inactivated vaccines to maintain their dominance in the market. An inactivated vaccine consists of defunct virus particles, bacteria, or other pathogens that have been grown in a lab and then killed off to incapacitate their capability to induce diseases. For example, in January 2022, GSK PLC, a biopharmaceutical corporation in the UK, launched an innovative inactivated vaccine for protection against shingles called Shingrix. Shingrix, a non-live, recombinant subunit adjuvanted vaccine, is delivered intramuscularly in two doses. Originally, the vaccine was intended for people aged 50 and above, but it has now been approved for those 18 years and older who are at an increased risk of acquiring shingles due to immunodeficiency or immunosuppression triggered by a recognized disease or therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13018

Which regions are emerging as leaders in the inactivated vaccines market?

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Rapidly is the Inactivated Vaccines Market Expected to Expand Between 2025 and 2034 Based on Current Trends?

The market size for inactivated vaccines has been consistently increasing in the last few years. It is expected to rise from $6.19 billion in 2024 to $6.44 billion in 2025, with a compound annual growth rate (CAGR) of 4.0%. The expansion during the historical timeframe was propelled by initiatives aimed at eradicating polio, influenza immunization schemes, the emergence of infectious diseases, and regulatory approvals.

The market size for deactivated vaccines is predicted to experience consistent expansion in the upcoming years, reaching a value of $7.75 billion in 2029 with a compound annual growth rate (CAGR) of 4.7%. This growth during the forecast period is due to preparedness for pandemics, increased vaccine coverage, advancements in biomanufacturing, and initiatives for health equity. Significant trends during this period are expected to include mRNA vaccine platforms, combined vaccines, thermostable vaccines, and digital vaccine passports.

What Drivers Are Shaping the Growth of the inactivated vaccines Market?

The rise in infectious diseases is anticipated to catalyze the growth of the inactivated vaccine industry in the coming years. These diseases, caused by pathogens like bacteria, viruses, fungi, or parasites, can be easily transmitted from one person to another, leading to a variety of symptoms and health issues. Tuberculosis, for example, is a common infectious disease. Inactivated vaccines employ dead pathogens to trigger an immune response, which helps prevent diseases such as polio, hepatitis A, and influenza. As per an article from the US-based Centers for Disease Control and Prevention in November 2023, the count of tuberculosis patients in the USA had surged from 8,320 in 2022 to 9,615 in 2023, indicating an increase of 1,295 cases. Consequently, the escalating prevalence of infectious diseases is fueling the expansion of the inactivated vaccine market.

Growth of Inactivated Vaccines Market Through Increasing Immunization Initiatives

 

Get Your Free Sample of the Global Inactivated Vaccines Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

Which Key Players Are Shaping the Future of the Inactivated Vaccines Market?

Major companies operating in the inactivated vaccines market are:

• Pfizer Inc._x000D_

• Johnson & Johnson Services Inc._x000D_

• Sinopharm Group Co. Ltd._x000D_

• Merck & Co. Inc._x000D_

• Sanofi S.A._x000D_

How Are the Latest Trends Influencing the Growth of the Inactivated Vaccines Market?

Leading firms in the inactivated vaccines market are striving to maintain their market presence by launching advanced and innovative inactivated vaccines. These vaccines consist of inactivated virus particles, bacteria, or other pathogens, which are cultured and subsequently killed to eliminate the disease-causing ability. For example, the UK-headquartered pharmaceutical and biotechnology firm, GSK PLC, launched an innovative inactivated vaccine called Shingrix in January 2022, aimed at improving protection against shingles (Herpes zoster). Shingrix, an intramuscularly administered non-live, recombinant subunit adjuvanted vaccine, was initially indicated for individuals aged 50 years and above. More recently, the scope of Shingrix has been widened to include individuals aged 18 and above who are at an increased risk of getting shingles due to immunosuppression or immunodeficiency associated with specific illnesses or treatments.

Get Instant Access to the Global Inactivated Vaccines Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Which Market Segments Are Driving Strategic Growth and Trends in the Inactivated Vaccines Market?

The inactivated vaccines market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine

2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

Subsegments:

1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

What Regions Are At the Forefront of Inactivated Vaccines Market Expansion?

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Can We Define the Inactivated Vaccines Market and Its Key Components?

Inactivated vaccines, also known as killed vaccines, are a type of vaccine that contains viruses or bacteria that have been killed or inactivated using heat, chemicals, or radiation. These vaccines are designed to stimulate an immune response without causing disease in the vaccinated individual.

Browse Through More Similar Reports By The Business Research Company:

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: